Global Hydroxychloroquine Market Overview
Hydroxychloroquine (HCQ) is also recognized as Hydroxychloroquine sulfate and sold under trade names Axemal, Plaquenil, Dolquine, Quensyl, Hydroquin, Quinoric, and Quineprox. It is a drug used primarily to prevent and treat malaria, which is caused by the mosquito of the Anopheles genus. Hydroxychloroquine is also used for the treatment of rheumatoid arthritis, lupus, Q fever, porphyria cutanea tarda, and COVID-19. This medicine is consumed orally and might cause some unwanted side effects, and can only be sold with a valid prescription. Hydroxychloroquine is needed to treat rheumatic disease during pregnancy. It belongs to a class of medications identified as disease-modifying antirheumatic drugs (DMARDs) and quinoline-containing antimalarial drugs. Moreover, it can reduce skin problems in systemic lupus erythematosus and prevent pain or swelling in arthritis sufferers. The Hydroxychloroquine Market accounted for US$ 1.6 billion in 2019 and is estimated to be US$ 2.7 billion by 2029 and is anticipated to register a CAGR of 5.3%
Impact of Covid-19 pandemic on market
The spread of coronavirus infection in countries worldwide has unexpectedly and rapidly increased from the first report of the outbreak in Wuhan, China, in December 2019. Currently, urgent initiatives and focus to develop a vaccine are ongoing in various countries globally. Trials for hydroxychloroquine are just beginning. Its toxicity, safety profile, and evidence-based clinical effectiveness against the virus are yet to be determined. India manufactures the majority share of hydroxychloroquine volume, and estimates for 70% of worldwide supply. Demand for hydroxychloroquine is projected to continue to increase as they search for a vaccine, treatment, and cure progresses, and focus on battling the COVID-19 intensifies. The report will account for Covid19 as a key market contributor.
Global Hydroxychloroquine Market Dynamics
Growth in the production of Hydroxychloroquine in India
India, a major manufacturer, and exporter of hydroxychloroquine. It is ramping up production to meet increased demand from a number of other countries, including the United States of America. India is giving away about 3 million tablets of the drug to the USA, and nine metric tons of API – Active Pharmaceutical Ingredient. Some of the top manufacturers in the Indian market are Intas Pharmaceuticals, Macleods Pharmaceuticals, McW Healthcare of Indore, and Cipla.
Manufacturers are ramping up their production capacities
Producers and suppliers operating in the target market have potential growth opportunities due to rising demand from end-use across the globe. Leading manufacturers such as Novartis, Teva, Mylan, etc. have provided hydroxychloroquine drugs at no cost to treat COVID-19 patients. Ipca Laboratories Ltd. has raised its production by 20 tons per month. Whereas, Laurus Labs has also increased its production capacity by 5 tons. Moreover, numerous companies like Laurus Labs, Bayer, Sun Pharma, etc. have promised to donate millions of hydroxychloroquine tablets in their respective regions.
However, side-effects of the drug can act as a key factor hampering demand to some extent. Other common effects include weakness, loss of appetite, tiredness, and headache.
Global Hydroxychloroquine Market Segmentation
The hydroxychloroquine market is segmented based on disease type, distribution channel, and region.
On the basis of disease type, the hydroxychloroquine market is segmented into coronavirus disease (COVID-19), malaria, Q fever, rheumatoid arthritis, lupus erythematosus, porphyria cutanea tarda (PCT), and other disease types. On the basis of the distribution channels, the target market is segmented into a specialty drug store, hospital pharmacies, retail pharmacies, and online pharmacy.
Regional Insights:
In the region, the hydroxychloroquine market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Canada, Mexico, and the U.S. is expected to register substantial gains by 2026. Rising coronavirus cases and a large number of clinical trials will lead to increased consumption of the product in the region, thus propelling the hydroxychloroquine market. India being a major manufacturer and exporter of hydroxychloroquine has already exported more than 3.5 million tablets coupled with more than 8.5 metric tons of ingredient to the U.S. for treatment of coronavirus.
|
Attribute |
Details |
|
The base year for estimation |
2019 |
|
Forecast period |
2019 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2019 – 2029 |
|
Market Segmentation |
By Disease Type- Coronavirus Disease (COVID-19), Malaria, Q Fever, Rheumatoid Arthritis, Lupus Erythematosus, Porphyria Cutanea Tarda (PCT), and Other Disease Types By Distribution Channel– Specialty Drug Store, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the hydroxychloroquine market report based on disease type, distribution channel, and region.
Hydroxychloroquine Market, By Disease Type:
- Coronavirus Disease (COVID-19)
- Malaria
- Q Fever
- Rheumatoid Arthritis
- Lupus Erythematosus
- Porphyria Cutanea Tarda (PCT)
- Other Disease Types
Hydroxychloroquine Market, By Distribution Channel:
- Specialty Drug Store
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Hydroxychloroquine Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Hydroxychloroquine Market Key Players
The key players operating in the hydroxychloroquine market include Novartis International AG, Mylan N.V., Wallace Pharmaceuticals Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Zydus Cadila Ltd., Ipca Laboratories Ltd., Cipla Limited, and Lupin Limited. Key players are focusing on volume expansion by implementing strategic decisions involving partnerships and collaborations. For instance, on March 30th, 2020 Intas declared about its collaboration on WHO certified studies for studying the effect of the hydroxychloroquine on coronavirus.
Global Hydroxychloroquine Market Company Profile
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Mylan N.V.
- Wallace Pharmaceuticals Ltd.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Zydus Cadila Ltd.
- Ipca Laboratories Ltd.
- Cipla Limited
- Lupin Limited
“*” marked represents similar segmentation in other categories in the respective section
Global Hydroxychloroquine Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Hydroxychloroquine Strategies
- Key Questions this Study will Answer
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Disease Type, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Coronavirus Disease (COVID-19)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Malaria
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Q Fever
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Rheumatoid Arthritis
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Lupus Erythematosus
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Porphyria Cutanea Tarda (PCT)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Other Disease Types
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Distribution Channel, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Specialty Drug Store
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Hospital Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Retail Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Online Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Disease Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Disease Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Disease Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Disease Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Disease Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Mylan N.V.
- Wallace Pharmaceuticals Ltd.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Zydus Cadila Ltd.
- Ipca Laboratories Ltd.
- Cipla Limited
- Lupin Limited
- Novartis International AG
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Hydroxychloroquine Market report segments the market basis of disease type, distribution channel, and region.
Producers and suppliers operating in the target market have potential growth opportunities due to rising demand from end-use across the globe. Leading manufacturers such as Novartis, Teva, Mylan, etc.
Asia-Pacific holds the maximum market share of the Hydroxychloroquines market.
The leading players operating in the Hydroxychloroquine Market include Novartis International AG, Mylan N.V., Wallace Pharmaceuticals Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Zydus Cadila Ltd., Ipca Laboratories Ltd., Cipla Limited, and Lupin Limited.